Know which portfolio companies are built to scale.
Score every portfolio company through one consistent, comparable framework — and see clearly, for the first time, which have built genuinely defensible IP positions and which haven't
Most VCs assess IP deal by deal, with no consistent framework to compare across a portfolio. The IPRSCORE™ changes that.
IP is a proven, leading indicator of high-growth, scalable companies. But without a standardized way to measure it. Result? Fragmented legal opinions and patent searches that miss four of the five IP asset classes that truly drive enterprise value
By scoring every portfolio company across five IP asset classes - Brand, Patents, Software, Critical Databases, and Trade Secrets - on a level playing field regardless of size, sector, stage, or geography, VCs can clearly see which companies have built genuinely defensible IP positions and which haven't.
The IPRSCORE™ is designed to act across your entire portfolio in one consistent, comparable framework.
High-scoring companies signal competitive moats built for scale and businesses worth backing harder.
Lower-scoring companies surface gaps, create value creation roadmaps, and give VCs the data to make earlier exit decisions with confidence.
→ Portfolio-wide IP benchmarking - every company scored consistently and comparably for the first time
→ Identify your strongest IP performers and highest-risk positions, with the data to act on both
→ Give portfolio companies a clear IP improvement roadmap, strengthening competitive moats and increasing valuations ahead of the next fundraise or exit
FAQs
We’ve Got the Answers You’re Looking For
How can the IPRSCORE™ help us benchmark and manage our portfolio?
How does the IPRSCORE™ help us identify which companies are genuinely built to scale?
What does the IPRSCORE™ tell us about our weaker performers?
Can the IPRSCORE™ help us when considering an early exit from a portfolio company?
Can the IPRSCORE™ help us assess whether a portfolio company is building long-term value for our investors?
Is the IPRSCORE™ relevant beyond early stage?